NCT05650320View on ClinicalTrials.gov

To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

February 17, 2023

Primary Completion Date

July 21, 2024

Study Completion Date

January 15, 2025

Conditions
Atopic Dermatitis (AD)
Interventions
DRUG

0.3% OPA-15406 Ointment

Twice-daily administration for 4 weeks.

DRUG

1% OPA-15406 Ointment

Twice-daily administration for 4 weeks.

OTHER

0% OPA-15406 vehicle

Twice-daily administration for 4 weeks.

Trial Locations (1)

100045

Beijing Children's Hospital, Capital Medical University, Beijing

Sponsors
All Listed Sponsors
lead

Otsuka Beijing Research Institute

INDUSTRY